Product
Axitinib + Etoposide
1 clinical trial
2 indications
Indication
MedulloblastomaIndication
EpendymomaClinical trial
MEPENDAX: Phase I/II Study of Axitinib (Inlyta®) and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and EpendymomaStatus: Not yet recruiting, Estimated PCD: 2026-04-01